Oppenheimer raised the firm’s price target on Catalyst Pharmaceuticals (CPRX) to $31 from $29 and keeps an Outperform rating on the shares. With Catalyst having reached a settlement with Teva (TEVA), the firm revised its model to reflect an updated outlook that Firdapse will not suffer generic competition until 2035,. It expects the remaining filers Hetero and Lupin to follow suit. The analyst anticipates greater visibility on the company’s largest revenue contributor will drive investment interest in the shares.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CPRX:
- Catalyst Pharmaceuticals price target raised to $35 from $30 at H.C. Wainwright
- Catalyst settlement with Teva a positive event, says BofA
- Catalyst Pharmaceuticals up 18% after resumption following Teva settlement
- Catalyst Pharmaceuticals trading resumes
- Catalyst Pharmaceuticals reports settlement of Firdapse patent litigation with Teva